This is an aggregated industry headline. Read the full story at FierceBiotech →
Novo Nordisk left praying to Artemis and Hermes to salvage CKD program after phase 3 fail
A phase 3 trial of Novo Nordisk's ziltivekimab has missed its primary endpoint, denting the prospects of a molecule analysts tipped to generate blockbuster sales and diversify the company's portfolio. Novo has chances to rescue the program with its ongoing Artemis and Hermes trials.
By FierceBiotech
· Aug 1, 2026
· via FierceBiotech
RxInsider combines reported facts with industry analysis and informed inference. Forward-looking reads, market commentary, and interpretive framing reflect analysis of available reporting and known facts, not confirmed outcomes.
Tags
theweekformat:headlineheadlineFierceBiotech
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from The Week
All The Week →
The WeekFiercePharma ↗
Amylyx's patient education website aims to empower patients to navigate post-bariatric hypoglycemia (PBH), a r…
The WeekBriefing
FiercePharma’s “The Top Line” highlighted three pressure points this week: M&A in psychedelics, peptide re…
The WeekSTAT News ↗
The Trump administration is revising its rebate pilot for the 340B drug discount program, angering hospitals.…